Tao Osgood

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.2K citations

Cancer Immunosurveillance, Clinical Kras, Immunology +5

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 408 citations · Full text

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun, Zhihong Li, Yosup Rew et al. · Journal of Medicinal Chemistry · 2014 · 290 citations · Full text

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

Yosup Rew, Daqing Sun, Felix González-López de Turiso et al. · Journal of Medicinal Chemistry · 2012 · 166 citations · Full text

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

Jude Canon, Tao Osgood, Steven H. Olson et al. · Molecular Cancer Therapeutics · 2015 · 144 citations

Amg 232, Tumor Biology, P53-inducing Cytotoxic Agents +13